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Abstract: Mantle cell lymphoma (MCL) is an aggressive lymphoma subtype with poor prognosis in 
which 18F-FDG-PET/CT role in treatment response evaluation and prediction of outcome is still 
unclear. The aim of this multicentric study was to investigate the role of 18F-FDG-PET/CT in staging 
MCL and the prognostic role of Deauville criteria (DC) in terms of progression-free survival (PFS) 
and overall survival (OS). We retrospectively enrolled 229 patients who underwent baseline and 
end-of-treatment (eot) 18F-FDG-PET/CT after first-line therapy. EotPET/CT scans were visually 
interpreted according to DC. The sensitivity, specificity, positive predictive value, negative 
predictive value and accuracy of PET/CT for evaluation of bone marrow (BM) were 27%, 100%, 
100%, 48% and 57%, respectively. The sensitivity, specificity, positive predictive value, negative 
predictive value and accuracy of PET/CT for evaluation of the gastrointestinal (GI) tract were 60%, 
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99%, 93%, 90% and 91%, respectively. At a median follow-up of 40 months, relapse occurred in 104 
cases and death in 49. EotPET/CT results using DC significantly correlated with PFS, not with OS. 
Instead, considering OS, only MIPI score was significantly correlated. In conclusion, we 
demonstrated that MCL is an FDG-avid lymphoma and 18F-FDG-PET/CT is a useful tool for staging 
purpose, showing good specificity for BM and GI evaluation, but suboptimal sensitivity. EotPET/CT 
result was the only independent significant prognostic factor that correlated with PFS. 
Keywords: mantle cell lymphoma; 18F-FDG PET/CT; prognosis; Deauville criteria 
 
1. Introduction 
Mantle cell lymphoma (MCL) accounts for 3% to 6% of all non-Hodgkin lymphoma and it is an 
aggressive lymphoma subtype with a high recurrence and mortality rate [1]. In the era of 
personalized and precision medicine, strong prognostic tools are needed in all lymphoma subtypes, 
such as MCL, to accurately predict possible further relapse of disease or death and to improve their 
treatment management. For this end-point, both clinical and imaging parameters are nowadays 
available, such as clinical scores and fluorine-18-fluorodeoxyglucose positron emission 
tomography/computed tomography (18F-FDG-PET/CT) derived parameters. MCL International 
Prognostic Index (MIPI) is the first prognostic index suited for MCL patients and may serve as an 
important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL [2]. 
At the same time, FDG-PET/CT at the end of first-line therapy is recognized as a powerful prognostic 
tool in many lymphoma subtypes. The Deauville score criteria (DC) and subsequent Lugano criteria 
were proposed in this setting and nowadays they are commonly accepted as a tool to evaluate 
response to treatment and prognosis in both interim and end-of-therapy setting in some lymphoma 
subtypes as in Hodgkin lymphoma (HL) and large B-cell lymphoma (DLBCL) [3,4]. For other less 
common lymphoma subtypes such as MCL, there is no clear scientific evidence of the role of these 
criteria in treatment evaluation and prognostication, although theoretically they can be considered 
valid. A recent editorial by Bailly et al. [5] underlined the lack of scientific evidences of a proven role 
of these criteria in MCL. Moreover, 18F-FDG-PET/CT at baseline has been recently evaluated to 
complete the staging of disease at diagnosis, with possible implication of different prognostic risk in 
the follow-up. The aim of this study was to evaluate the role of 18F-FDG-PET/CT in patients with 
MCL as follows: assessing its power in staging MCL; evaluating DC as a predictive tool in response 
to therapy and as a prognostic tool in terms of progression-free survival (PFS) and overall survival 
(OS); testing the combination of clinical and imaging parameters in order to identify different risk 
classes able to predict the outcomes. 
2. Results 
2.1. Tumor Characteristics 
Among 229 patients with histological proven MCL, there was a prevalence of male (n = 172) 
compared to female (n = 57); the average age was 65.1 years (range: 29–88). Patients were staged 
according to the Ann Arbor system as follows: stage I (n = 4), stage II (n = 9), stage III (n = 32) and 
stage IV (n = 184). B-symptoms, bulky disease and splenomegaly were described in 65, 40 and 101 
patients, respectively. LDH level resulted high in 93 cases, β2-microglobulin in 65 and MIPI score 
was greater than 6 in 130 patients. Proliferative index Ki-67 was available in 183 patients, being low 
in 65 (36%) and high in 118 (64%) subjects. Baseline features of the patients are summarized in Table 
1.  
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Table 1. Baseline features of our population. 
Variables Patients n (%) Average (Range) 
Age (years) 65.1 (29–88) 
Sex 
 male 172 (75%)  
 female 57 (25%)  
Tumor stage at diagnosis (Ann Arbor) 
 I 4 (2%)  
 II 9 (4%)  
 III 32 (14%)  
 IV 184 (80%)  
Blastoid variant 26 (11%)  
B symptoms 65 (28%)  
LDH 
 ≤245 U/L 121 (57%)  
 >245 U/L 93 (43%)  
β2-microglobulin 
 ≤2.8 mg/L 108 (62%)  
 >2.8 mg/L 65 (38%)  
MIPI score 
 low-intermediate (≤6) 99 (43%)  
 high-intermediate (>6) 130 (57%)  
Bulky disease 40 (17%)  
Splenomegaly 101 (44%)  
Ki-67 score 
 ≤15% 65 (36%)  
 >15% 118 (64%)  
LDH: lactate dehydrogenase; MIPI: mantle cell lymphoma international prognostic index. 
2.2. 18F-FDG PET/CT Evaluation for Initial Staging 
All patients had abnormal 18F-FDG PET/CT showing the presence of at least one lesion with 
increased FDG uptake consistent with MCL. 18F-FDG PET/CT scans detected nodal disease in 216 
(94%) patients. Splenic involvement was detected by PET/CT in 100 (44%) patients. 
Considering bone marrow (BM) biopsy as reference, BM disease was reported in 136 (59%) 
patients, while 18F-FDG PET/CT showed a focal uptake, compatible with BM involvement, in 37 
(16%) subjects. Sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive 
value (NPV) and accuracy (AC) of 18F-FDG-PET/CT in evaluating BM were 27% (20–35%), 100% (96–
100%), 100%, 48% (46–51%) and 57% (50–63%); negative likelihood ratio was 0.73. No false positive 
findings for BM involvement were registered at PET/CT; however, 99 false negative findings were 
registered (Table 2). Agreement between the two techniques was low (Cohen’s k = 0.23). 
Table 2. Agreement between 18F-FDG PET/CT and BM biopsy and GI endoscopy findings. 
PET/CT Findings 
BM Biopsy GI Endoscopy 
Positive Negative Positive Negative 
Positive 37 (16%) 0 (0%) 28 (12%) 2 (1%) 
Negative 99 (43%) 93 (41%) 19 (8%) 180 (79%) 
Total 136 (59%) 93 (41%) 47 (21%) 182 (79%) 
BM: bone marrow; GI: gastrointestinal. 
18F-FDG PET/CT resulted positive for gastrointestinal (GI) tract involvement in 30 (13%) cases: 
among them, in 13 showing gastric uptake, 1 in gastro-duodenal junction uptake, 2 in the duodenum, 
12 in the colon, 1 in sigma and 1 in the cecum. Considering GI endoscopy as standard of reference, 
47 patients had a GI involvement of MCL. SE, SP, PPV, NPV and AC of 18F-FDG-PET/CT were 60% 
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(44–74%), 99% (96–100%), 93% (78–98%), 90% (87–93%), 91% (86–94%) respectively; positive and 
negative likelihood ratios were 54.21 and 0.41, respectively (Table 2). Agreement between the two 
techniques was quite good (Cohen’s k = 0.67). 
2.3. Role of 18F-FDG PET/CT in Predicting Survival 
2.3.1. Application of Deauville Criteria 
According to DC, 186 (81%) patients were categorized as eotPET negative (score 1–3) (Figure 1) 
and 43 (19%) as a positive scan (score 4–5) (Figure 2). At a median follow-up of 40 months, relapse 
and/or progression of lymphoma was found in 104 patients with a mean time of 31.2 months (range: 
3–145) from the diagnosis, and death was found in 49 cases with a mean time of 33.9 months (range 
3–145). Considering patients with relapse/progression of disease, a negative eotPET/CT scans 
applying DC were registered in 74 cases, whilst a positive scan in 30 (in particular, Deauville score 4 
in thirteen cases and Deauville score 5 in seventeen). Instead, among patients who died during the 
course of the disease, eotPET/CT applying DC was positive in 20 (in particular, score 4 in seven cases 
and score 5 in thirteen) and negative in 27 (in particular, score 1 in 17 subjects, score 2 in nine and 
score 3 in one). Patients with eot positive PET/CT underwent subsequent second-line chemotherapy 
regimen according to institutional protocol. 
 
Figure 1. Emblematic example of complete metabolic response. A representative case of a 56-year-old 
male with stage III MCL. (a) Baseline maximum intensity projection (MIP), showing diffuse 
hypermetabolic disease in (b) laterocervical, (c) mediastinal and (d) iliac nodes. (e) PET/CT after 
chemotherapy showing a complete metabolic response (Deauville score 1) with no 18F-FDG uptake 
(f–h) with the disappearance of previous lesions. 
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Figure 2. Emblematic example of progressive disease. A representative case of a 65-year-old male 
with stage III MCL. (a) Baseline maximum intensity projection (MIP, showing diffuse hypermetabolic 
disease in (b) laterocervical, axillary, (c) iliac and (d) inguinal nodes and in spleen. (e) PET/CT after 
chemotherapy showing a metabolic progression of disease (Deauville score 5) with the appearance of 
new lesions (f–h). 
The median PFS and OS were 28 months (range 3–145 months) and 34 months (range 3–145 
months) respectively; with estimated 2-year PFS and OS rates of 73% and 84%, and 3-year PFS and 
OS rates of 56% and 75%, respectively. 
At univariate analysis, DC and MIPI score were the only parameters significantly related to PFS 
(Figure 3); other clinical/pathological features (sex, age, splenomegaly, bulky disease, stage, blastoid 
variant, β2-microglobulin and LDH level) were not associated with the outcome. PFS was 
significantly shorter in patients with eotPET/CT DC positive compared to negative (12 vs. 32 months, 
p < 0.001). At multivariate analysis, only metabolic feature (Deauville score) was confirmed to be an 
independent prognostic factor for PFS (p < 0.001). Combining DC (≤3 and >3) and MIPI score (≤6 and 
>6), PFS was significantly longer in eotPET negative patients independently from MIPI score (p < 
0.001) (Figure 4). Median PFS was 82 months in patients with low-intermediate MIPI score (≤6) and 
a negative eotPET/CT (DC ≤ 3); 62 months in patients with high MIPI score (>6) and a negative 
eotPET/CT; 25 months in patients with low-intermediate MIPI score and a positive eotPET/CT (DC 4 
or 5), and 12 months in patients with high MIPI score and a positive eotPET/CT. 
Instead, considering OS, only MIPI score resulted as significantly correlated (Figure 5), both at 
univariate and multivariate analysis (p = 0.017) (Table 3). EotPET/CT according to DC did not predict 
OS (31 vs. 37.5 months, p = 0.814) (Figure 5). 
Treatment regimen (R-CHOP regimen vs. other chemotherapy regimen) did not influence 
outcome survival considering both PFS and OS.  
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Figure 3. Progression-free survival (PFS) curves according to end-of-treatment PET/CT results using 
(a) Deauville criteria and (b) MIPI score. 
 
Figure 4. Progression-free survival curve combining MIPI score and Deauville score groups. 
 
Figure 5. Overall survival (OS) curves according to end-of-treatment PET/CT results using (a) 
Deauville criteria and (b) MIPI score. 
Table 3. Univariate and multivariate analyses for PFS and OS. 
Variables 
Univariate Analysis Multivariate Analysis 
p-value HR (95% CI) p-value HR (95% CI) 
PFS 
Sex 0.451 0.845 (0.548–1.306)   
Age 0.153 1.530 (0.838–3.097)   
MIPI score 0.009 0.713 (0.482–1.056) 0.174 1.219 (0.915–1.623) 
LDH level 0.163 0.742 (0.488–1.128)   
Β2 microglobulin 0.458 0.831 (0.511–1.353)   
Ki-67 score 0.066 0.653 (0.415–1.028)   
Bulky disease 0.153 1.722 (0.992–2.987)   
Splenomegaly 0.087 0.703 (0.472–01049)   
Stage acc Ann Arbor 0.855 0.957 (0.589–1.531)   
Blastoid variant 0.185 0.598 (0.282–1.270)   
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Deauville score <0.001 0.137 (0.073–0.259) <0.001 4.059 (2.573–6.403) 
Treatment regimen 0.655 0.857 (0.519–1.243)   
OS 
Sex 0.211 1.759 (0.577–6.033)   
Age 0.375 1.270 (0.722–2.369)   
MIPI score 0.025 0.711 (0.527–0.959) 0.017 1.204 (1.032–1.403) 
LDH level 0.709 0.942 (0.690–1.287)   
Β2 microglobulin 0.524 1.128 (0.778–1.635)   
Ki67 score 0.195 1.250 (0.891–1.754)   
Bulky disease 0.390 0.828 (0.539–1.272)   
Splenomegaly 0.287 0.846 (0.622–1.150)   
Stage acc Ann Arbor 0.393 0.859 (0.606–1.217)   
Blastoid variant 0.075 0.618 (0.363–1.051)   
Deauville score 0.814 1.055 (0.671–1.660)   
Treatment regimen 0.598 1.001 (0.571–1.460)   
PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; N: 
number. 
3. Discussion 
MCL is an aggressive B-cell non-Hodgkin lymphoma with a fast-growing course, high-risk of 
relapse and need for early treatment. Patients affected by MCL typically present with advanced-stage 
disease and extranodal involvement with a predilection for BM and GI tract, where routine 
conventional techniques such as CT have a suboptimal accuracy [6]. A correct and an early 
identification of initial and extranodal disease may be crucial because it could potentially affect 
patient’s management and therapeutic choice. 18F-FDG PET/CT has shown a high accuracy in the 
detection of nodal involvement [7–9], but a low sensitivity in BM and GI tract, being inadequate to 
replace BM biopsy and GI endoscopy in disease staging [10–12]. In the present study, we 
demonstrated a very low sensitivity of PET/CT in the evaluation of BM involvement (27%), but with 
a specificity equal to 100%. No case of false-positive findings on BM at PET/CT were recorded, but 
there were 99 cases of false-negative PET. Thus, the need for BM biopsy seems to be mandatory in 
case of negative BM PET/CT. Previous studies [10–12] reported a very low pretreatment PET scan 
accuracy to detect BM involvement, very low with sensitivity ranging from 12% to 51%. A 
comparison between our paper and others is not easy due to the different population number and 
features evaluated. Recently, Morgan et al. [13] projected a voxel-based analysis of the iliac bones for 
classifying BM disease in MCL founding a good sensitivity and specificity (100% and 87.5%, 
respectively); this method seems to be very promising but less practical and reproducible and it has 
been validated only on a small sample of patients. The potential role of 18F-FDG PET/CT in 
evaluating lymphoma BM involvement remains a challenge; this is a non-invasive technique well 
studied in HL and DLBCL, but with controversial and limited evidence [14,15]. Several studies have 
proven that 18F-FDG PET/CT can be an accurate method for the evaluation of BM involvement in 
patients affected by DLBCL considering focal highly 18F-FDG-avid lesions as reference standard; on 
the other hand the absence of a focal uptake does not exclude the presence of BM involvement. Our 
results confirmed similar evidences also in MCL, suggesting to avoid a BM biopsy in case of positive 
PET/CT scan. 
Also, for the GI tract, our results showed that 18F-FDG PET/CT revealed a good specificity but 
a low sensitivity (60%), being in agreement with other published papers [9,12,16]. It was already 
demonstrated that an increased 18F-FDG bowel uptake may be common, especially in diabetic 
patients [17,18], thus reducing the diagnostic accuracy of the evaluation of this district. 
Another crucial topic to consider in MCL is the prognostication; nowadays, neither clinical nor 
imaging prognostic markers are available in MCL setting. MIPI score [2] was an attempt created to 
better classify patients with MCL and predict prognosis, but its validation has shown conflicting 
results [19,20]. Other histopathological features, such as blastoid variant and Ki-67 score, have been 
investigated without shared evidence [21]. Instead, the prognostic value of 18F-FDG-PET/CT in MCL 
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remains under debate [16,22–25]. In 2009, a five-point scale system called Deauville criteria (DC) was 
introduced to analyze 18F-FDG PET/CT results after treatment in lymphoma [26]; this scale used the 
mediastinum and liver activity as the reference standard, and has been recommended for reporting 
both interim and end-of-treatment PET for FDG-avid lymphoma (both HL and NHL, especially 
DLBCL) [3,4,27]. In our paper, we tried to validate this score also in MCL, obtaining some strong 
results; patients with a negative end-of-treatment PET/CT (DC1-3) had significantly longer PFS than 
patients with a positive PET/CT (DC4,5). Similar results in small cohort of patients were reported by 
other authors [20,22,28]. However, this evidence was not confirmed for OS, where DC seems to not 
influence the outcome survival. This could be explained to the fact that eotPET/CT results were used 
to guide subsequent management and further treatments, as second-line chemotherapy regimen. 
The treatment of MCL is a challenge and often stays unsatisfactory; complete responses to the 
standard chemotherapy regimens are not common. Czuczman et al. [29] in a multicenter open-label 
single-arm phase II study showed that the complete metabolic response at PET/CT was a predictor 
of outcome survival. In addition to qualitative 18F-FDG PET/CT analysis using DC, also 
semiquantitative PET/CT parameters have been studied as prognostic factors, like SUVmax, with 
controversial results. Karam et al. [30] and Bodet-Milin et al. [16], in patients affected by MCL, 
suggested SUVmax thresholds of 5 and 6, respectively, to stratify patients into high-risk versus low-
risk groups and to predict OS and disease-free survival. On the other hand, no prognostic impact of 
SUVmax was demonstrated by other groups [10,12,24]. Recently in the LyMa-PET Project [23], it was 
demonstrated that SUVmax was the only independent prognostic factor for PFS and OS; moreover, 
authors suggested a scoring system combining MIPI and SUVmax (using a cutoff of 10.3) to help the 
outcome prediction. In our study, eotPET/CT results using DC were superior than the MIPI score in 
PFS, while for OS only the MIPI score resulted as an independent prognostic factor. 
Instead, no clinical or histological variables, like blastoid variant and Β2 microglobulin, showed 
significant association with outcome survival in our analysis; this is partially in contradiction with 
literature [1] and related probably to heterogeneity of population studied. 
Also, Ki-67 score seems not to be related to PET/CT features and outcome survival despite that 
in other lymphoma subtypes significant correlation was demonstrated [31,32]. 
The present study has some limitations. First, this is a retrospective multicentric study, so 
heterogeneous features in our population in terms of clinical baseline parameters and treatment 
schemes could be found. Despite this, so far and to best of our knowledge, the present study is the 
first large series of MCL patients aimed to assess the diagnostic and prognostic role of 18F-FDG 
PET/CT. Second, although this study showed the independent prognostic value for PFS of end-of-
treatment PET/CT, the role of semi-quantitative PET/CT parameters, in terms of SUVs, should be 
further analyzed. Third, more complex statistical analysis, like a deep learning approach, might have 
improved data analysis. 
4. Materials and Methods 
4.1. Patients 
Between January 2007 and December 2018 in nine Italian Nuclear Medicine Centers, 229 patients 
with newly diagnosed, histologically proven MCL were retrospectively enrolled. The 
histopathological diagnosis was based on the World Health Organization criteria [33]. The inclusion 
criteria were as follows: patients with a histological confirmation of MCL; age ≥18 years; availability 
of BM biopsy and GI endoscopy at time of diagnosis; availability of baseline and end of treatment 
18F-FDG PET/CT results in all patients; and availability of clinical/radiologic follow-up data for at 
least 12 months. Patients with concomitant malignancies were excluded. We further reviewed the 
follow medical records of these patients: epidemiological features (age at diagnosis, sex), clinical data 
(tumor stage, MIPI score, bulky disease, splenomegaly, B symptoms, lactate-dehydrogenase (LDH) 
level, β2-microglobulin level), histopathological data (Ki-67 score, blastoid variant), metabolic 
features by 18F-FDG PET/CT, treatment modalities and follow-up data. LDH level, β2-microglobulin 
and MIPI score were dichotomized using cutoff values of 245 U/L, 2.8 mg/L and 6 respectively. Tumor 
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stage according to Ann Arbor classification was divided in early (I and II) and advanced (III and IV) 
disease. The bulky disease was defined when the maximum width was equal or greater than one-
third of the internal transverse diameter of the thorax or at an alternative site as any mass measuring 
10 cm or more by any imaging study. Proliferative activity, expressed by Ki-67 score, was available 
in 183 patients; average Ki-67 was 25% (range 1–95%). The Ki-67 expression level was arbitrarily 
dichotomized using a cut-off of 15% as suggested by other authors [24,34]. 
All patients were treated according to the institution’s standard protocol with chemotherapy 
regimen related to the stage of disease, age and institutional internal protocol. Eighty-two patients 
were treated according to R-CHOP (Rituximab, Cyclophoshpamide, Hydroxydaunomycin, Oncovin, 
Prednisone) regimen, sixty-eight with R-DHAP (dexamethasone, cytarabine, cisplatin), thirty-nine 
with R-Bendamustina, twenty-four with BCVPP (Carmustine, Cyclophosphamide, Vinblastine, 
Procarbazine, and Prednisone), twelve with MBVD (Myocet+BVD). In one case, chemotherapy was 
followed by the involved field radiotherapy. Four patients (2%) underwent only radiotherapy due to 
the early stage of disease (stage I). 
4.2. 18F-FDG PET/CT Imaging and Interpretation 
All patients underwent baseline 18F-FDG PET/CT and a subsequent PET/CT at completion of 
first-line therapy (eotPET/CT). PET/CT studies were performed following EANM guidelines [35]. 
Baseline PET/CT was performed within 14 days before the first cycle of chemotherapy and end-of-
treatment PET/CT was done at least three weeks after the completion of chemotherapy or 12 weeks 
after completion of radiotherapy. 
18F-FDG-PET/CT was performed after at least 6 h of fasting and with glucose level lower than 
150 mg/dL. An activity of 3.5–4.5 MBq/Kg of 18F-FDG was administered intravenously and scans 
were acquired about 60 min after injection, usually from the skull basis to the mid-thigh. Owing to 
the multicenter nature of the study, the exams were acquired on different PET/CT scanners: 
Discovery STE or 690 (GE Healthcare Technologies, Milwaukee, Wisconsin, USA), Discovery IQ (GE 
Healthcare Technologies), Discovery LS (GE Healthcare Technologies), Gemini TFEGXL (Philips 
Medical Systems, Cleveland, OH, USA) and Biograph 16 (Siemens Healthcare, Erlangen, Germany). 
Standard parameters used were: CT: 80 mA, 120 Kv without contrast; 2.5–4 min per bed-PET-step of 
15 cm; the reconstruction was performed in a 128 × 128 matrix and with a 60 cm field-of-view. 
Patients were instructed to void before imaging acquisition, no oral or intravenous contrast 
agents were administrated and no bowel preparation was used for any patient; written consent was 
obtained before studies. The PET images were visually analyzed and readers had knowledge of 
clinical history. PET/CT scans were interpreted visually by two nuclear medicine physicians (DA, 
SA) with experience in this field and the discordance was resolved by a consensus between the two 
imaging readers. 
For the interpretation of images, each focal tracer uptake deviating from physiological 
distribution and background and uptake higher than liver activity was considered as suggestive for 
lymphoma. 
In the evaluation of BM involvement, PET/CT findings were considered positive in the presence 
of isolated/multiple focal uptakes in the BM that could not be explained by benign findings on the 
underlying CT scan or patient’s medical history (like fractures, spondylodiscitis, etc.). In the 
evaluation of GI involvement, PET/CT findings were considered positive in the presence of 
isolated/multiple intense focal uptakes in the GI tract. Accuracy of 18F-FDG PET/T results was 
evaluated considering further evaluations: lesions with 18F-FDG PET/CT uptakes were considered 
as true-positives if further analyses confirmed the malignant nature, and false-positive if further 
evaluations showed no malignant lesions. Lesions without 18F-FDG PET/CT uptakes were 
considered as true negative if further analyses confirmed the absence of neoplastic lesions and false-
negative if further evaluations showed malignant ones. Eot 18F-FDG PET/CT was interpreted by 
visual analysis using the Deauville 5-point scale [4]. According to Deauville Criteria (DC), 18F-FDG 
PET was interpreted as follows: 1 = no uptake above background, 2 = uptake equal to or lower than 
mediastinum, 3 = uptake higher than mediastinum and lower than liver, 4 = uptake moderately 
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increased compared to the liver and 5 = uptake markedly increased compared to the liver. Eot 18F-
FDG PET/CT scans were considered negative for scores 1 to 3 and positive for scores 4 to 5. 
4.3. Statistical Analysis 
Our statistical analysis was carried out using MedCalc Software version 17.1 for Windows 
(Ostend, Belgium). Categorical variables were described as the calculation of simple and relative 
frequencies, while the numeric variables were described as average, minimum and maximum. We 
calculated SE, SP, PPV, NPV and AC based on Bayes’s law, with 95% confidence intervals, 
considering final diagnosis as a reference. 
The PFS was calculated from the date of diagnosis of MCL to the date of first relapse, progression 
of disease or the last follow-up date. The OS was calculated from the date of diagnosis of MCL to the 
date of death from any cause or the last follow-up date. 
Survival curves were plotted according to the Kaplan–Meier method and differences between 
several groups were investigated by using a two-tailed log rank test. Cox regression was used to 
evaluate the hazard ratio (HR) and its confidence interval (CI). A p-value of <0.05 was considered 
statistically significant and the adjusted significant p-value after Bonferroni’s correction was 0.038. 
5. Conclusions 
In conclusion, in this study, we demonstrated that MCL is an FDG-avid lymphoma and that 18F-
FDG PET/CT is a useful tool for staging purpose, which should be considered in the diagnostic flow-
chart of this patients in concert with other modalities. 
PET/CT showed good specificity for BM and GI evaluation but suboptimal sensitivity. 
Moreover, eotPET post-therapy PET/CT results, evaluated according to Deauville criteria, can be 
considered powerful prognostic information in order to stratify the progressive patients. 
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